Drug Profile
Alpha 1 antitrypsin - CSL Behring
Alternative Names: AAT - CSL Behring; Alpha-1 proteinase inhibitor - CSL Behring; Alpha-antitrypsin - CSL Behring; API; API Inhale; CSL 964; Respreeza; ZemairaLatest Information Update: 04 Jan 2024
Price :
$50
*
At a glance
- Originator CSL Behring
- Developer Blood and Marrow Transplant Clinical Trials Network; CSL Behring; Nektar Therapeutics
- Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Antiallergics; Antihyperglycaemics; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
- Mechanism of Action Alpha 1-antitrypsin replacements; Immunomodulators; Serine endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Alpha 1-antitrypsin deficiency
- Phase III Graft-versus-host disease
Most Recent Events
- 02 Jan 2024 Preregistration for Alpha 1-antitrypsin deficiency in Puerto Rico, Mexico (IV), prior to January 2024
- 02 Jan 2024 Registered for Alpha 1-antitrypsin deficiency in Puerto Rico, Mexico (IV), prior to January 2024
- 17 Nov 2021 Phase-III clinical trials in Graft-versus-host disease (In adolescents, Prevention, In adults) in Spain, USA, Australia, United Kingdom, Italy, Germany (IV) before November 2021 (CSL Behring pipeline, November 2021)